In short
This article discusses a Phase 1 clinical trial investigating the use of RP-1664 Sulfate, a novel drug developed by Repare Therapeutics, for patients with advanced solid tumors. The trial aims to assess the safety, effectiveness, and optimal dosing of RP-1664, which is an inhibitor of Polo-Like Kinase 4 (PLK4). This study represents an important step in developing new treatment options for patients with advanced cancers who have limited therapeutic choices.
At a glance
- Drug Name
- RP-1664 Sulfate
- Drug Type
- Inhibitor of Polo-Like Kinase 4 (PLK4)
- Administration
- Oral capsules
- Target Condition
- Advanced Solid Tumors
- Trial Phase
- Phase 1
- Primary Objectives
- Assess safety, tolerability, and determine optimal dose
- Secondary Objectives
- Evaluate pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity
- Key Eligibility Criteria
- Adults with advanced solid tumors, TRIM37 gain/amplification, measurable disease
- Study Design
- Dose escalation followed by expansion cohorts
What is RP-1664?
RP-1664 SULFATE is a new drug being developed by Repare Therapeutics for the treatment of advanced solid tumors. It is currently in the early stages of clinical testing, specifically in a Phase 1 trial. This means that while the drug shows promise in laboratory studies, it is still being evaluated for safety and effectiveness in humans.
How does RP-1664 work?
RP-1664 is classified as an inhibitor of Polo-Like Kinase 4 (PLK4). Polo-Like Kinase 4 is an enzyme that plays a crucial role in cell division. By inhibiting this enzyme, RP-1664 may be able to interfere with the rapid cell division that is characteristic of cancer cells, potentially slowing down or stopping tumor growth.
What conditions does RP-1664 treat?
RP-1664 is being studied for the treatment of advanced solid tumors. Solid tumors are abnormal masses of tissue that don't contain cysts or liquid areas. They may occur in various parts of the body, such as the breast, lung, prostate, or colon. The term "advanced" typically means that the cancer has spread from where it started to other parts of the body or is at a later stage.
Current Research
The ongoing Phase 1 trial for RP-1664 has several objectives:
- To assess the safety and tolerability of RP-1664 in patients with advanced solid tumors
- To determine the best dose and schedule for the drug
- To study how the drug is processed by the body (pharmacokinetics)
- To evaluate the preliminary anti-tumor activity of RP-1664
The researchers will be looking at various factors, including:
- The frequency and severity of side effects
- How the drug is absorbed, distributed, and eliminated from the body
- Whether tumors shrink or stop growing in response to the treatment
- How long patients survive without their cancer progressing
Who can participate in the trial?
The trial is open to adult patients (18 years or older) with advanced solid tumors that have not responded to, or have progressed after, standard treatments. Some key eligibility criteria include:
- Having a life expectancy of at least 4 months
- Being in relatively good overall health (able to perform daily activities with little assistance)
- Having measurable disease that can be evaluated for response to treatment
- Having a tumor with a specific genetic characteristic: gain or amplification of a gene called TRIM37
There are also several factors that would exclude a person from participating, such as certain medical conditions or prior treatments.
How is RP-1664 administered?
RP-1664 is given as an oral medication in the form of hard capsules. This means patients can take the drug by mouth, which is often more convenient than medications that need to be injected or given intravenously.
Safety and Side Effects
As this is a Phase 1 trial, one of the main goals is to assess the safety of RP-1664. The researchers will be closely monitoring all participants for any side effects or adverse reactions to the drug. It's important to note that at this early stage, not all potential side effects may be known.
The trial includes careful monitoring of patients' organ function, blood counts, and overall health status. Patients will also be regularly assessed for any signs of tumor response or progression.
It's crucial to remember that RP-1664 is still in the early stages of testing. While it shows promise, more research is needed to fully understand its effectiveness and safety profile. Patients considering participation in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.